Where is the manufacturer behind neratinib maleate/neratinib tablets?

Neratinib, also known as neratinib (Neratinib), is launched in the Chinese market in the form of neratinib maleate tablets and has become one of the important drugs for the treatment of HER2-positive breast cancer. This drug has a unique anti-cancer mechanism, that is, by inhibiting the tyrosine kinase activity of human epidermal growth factor receptor HER1 (EGFR), HER2 and HER4, blocking the signal transduction pathways of cancer cells, thereby achieving the purpose of controlling cancer development.

The initial development of neratinib was undertaken by Wyeth (now part of Pfizer). However, during the long process of drug research and development, with various cooperation and transfers, the subsequent research and development and production rights of neratinib finally fell into the hands of Puma Biotechnology. As a company focused on the research and development of innovative drugs in the field of cancer treatment, Puma Biotechnology invested a lot of manpower, material and financial resources after taking over the neratinib project to ensure that this drug can move smoothly from the laboratory to the market.

Puma Biotechnology has world-class R&D facilities and production lines, as well as an R&D team composed of top industry experts. During the R&D and production of neratinib, the company always follows international drug production standards and strictly controls every link to ensure the quality and safety of the final product. This ultimate pursuit of drug quality and deep concern for patient safety have enabled the neratinib maleate tablets produced by Puma Biotechnology to win widespread recognition and praise around the world.

It is worth mentioning that after its launch, neratinib tablets not only provided a new treatment option for patients with early-stage hormone receptor-positiveHER2 overexpression/amplification breast cancer, it was also approved in the United States in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer. These achievements undoubtedly further prove Puma Biotechnology's outstanding strength and profound foundation in the field of anti-cancer drug research and development.